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Introduction
Spinal muscular atrophy (SMA) is an autosomal recessively 
inherited neuromuscular disorder caused, in the majority of 
patients (~95%), by homozygous deletion in the Survival 
Motor Neuron gene 1 (SMN1). It is characterized by the 
selective degeneration of lower motor neurons and limb and 
trunk muscle weakness due to the deficiency of SMN pro-
tein. SMN protein is ubiquitously expressed. While SMA is 
generally described as a lower motor neuron disease with 
spinal motor neurons being the primary pathological target, 
increasing numbers of clinical and experimental reports indi-
cate the involvement of additional peripheral organs which 
may contribute to the pathogenesis of the disease, espe-
cially in severe cases.1 SMA is currently incurable, however, 
experimental therapies, i.e., antisense oligonucleotide (AON) 
therapy,2–6 viral-vector–mediated gene therapy,7–10 and small 
molecule therapy,11,12 have shown promising preclinical effi-
cacy. AON therapy on IONIS-SMNRx (Nusinersen) is now in 
phase 3 clinical trial, with encouraging data on safety and 
clinical outcomes from the earlier phase 1 clinical trial.13 
Small molecule and SMN1 gene therapy (AVXS-101) are 
also in early phase clinical trials.
MicroRNAs (miRNAs) are a class of small (~22nt) endoge-
nous non-protein-coding RNA molecules that are involved in 
fine regulation of gene and protein expression across multiple 
tissues. Dysregulation of specific miRNAs is associated with 
pathological processes and various disease states. In neuro-
muscular diseases, a number of miRNAs have been studied 
as biomarkers in Duchenne muscular dystrophy (DMD) and 
to measure the response of the mdx mouse model of DMD 
to AON therapy.14–16 Interestingly, specific serum miRNA pro-
files have been found to be associated with distinct muscular 
dystrophies in mouse models.17
The hallmark in SMA mouse models is the loss of lower 
motor neurons following the defects in neuromuscular junc-
tions due to the primary SMN deficiency. In vitro, the loss 
of SMN function disrupts axonal extension and pathfinding.18 
Numerous studies have shown that miRNAs are key factors 
in regulating the development of the nervous system. The 
most direct evidence comes from a study in which disrupting 
miRNA biogenesis pathway by deleting Dicer1 from spinal 
motor neurons in mice caused an SMA-like phenotype and 
downregulation of miR-9 (ref. 19). miR-9 also regulates axon 
extension and branching in mouse cortical neurons.20 In addi-
tion to its role in the central nervous system, the dicer-miRNA 
pathway is also required for peripheral nerve regeneration 
and functional recovery in vivo and axonal reoutgrowth 
in vitro.21 Indeed, deletion of Dicer in the mouse sciatic nerve 
suggested that functional miRNAs are crucial for nerve 
regeneration and axonal regrowth.21 Another miRNA that 
plays an essential role in neuron dendritic outgrowth22 and 
synaptic function23 is miR-132. Both miR-9 and miR-132 can 
delay neurite outgrowth in vitro and impair the radial neuronal 
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The identification of noninvasive biomarkers to monitor the disease progression in spinal muscular atrophy (SMA) is becoming 
increasingly important. MicroRNAs (miRNAs) regulate gene expression and are implicated in the pathogenesis of neuromuscular 
diseases, including motor neuron degeneration. In this study, we selectively characterized the expression of miR-9, miR-206, and 
miR-132 in spinal cord, skeletal muscle, and serum from SMA transgenic mice, and in serum from SMA patients. A systematic 
analysis of miRNA expression was conducted in SMA mice with different disease severities (severe type I-like and mild type III-
like) at different disease stages (pre-, mid-, and late-symptomatic stages), and in morpholino antisense oligonucleotide-treated 
mice. There was differential expression of all three miRNAs in spinal cord, skeletal muscle and serum samples in SMA mice. 
Serum miRNAs were altered prior to the changes in spinal cord and skeletal muscle at the presymptomatic stage. The altered 
miR-132 levels in spinal cord, muscle, and serum transiently reversed to normal level after a single-dose morpholino antisense 
oligomer PMO25 treatment in SMA mice. We also confirmed a significant alteration of miR-9 and miR-132 level in serum samples 
from SMA patients. Our study indicates the potential of developing miRNAs as noninvasive biomarkers in SMA.
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migration in embryonic mouse neocortex in vivo.24 In addi-
tion, miR-132 is involved in the process of neovasculariza-
tion,25 and recent reports have highlighted vascular defects in 
both skeletal muscle and spinal cord of SMA.26,27
The muscular dystrophic phenotype in SMA is thought to 
be caused by skeletal muscle denervation secondary to spi-
nal motor neuron defects. Direct correlation has also been 
identified between SMN deficiency and disruption of the 
myogenic program.28,29 miR-206 is a skeletal muscle specific 
miRNA involved in the formation of myofibers and differen-
tiation of satellite cells.30 It plays a neuroprotective role in 
the regeneration of neuromuscular junction in amyotrophic 
lateral sclerosis. Knocking-out miR-206 in the amyotrophic 
lateral sclerosis mouse model accelerates disease progres-
sion.31 miR-206 is required for regeneration of neuromuscu-
lar synapses after acute nerve injury.31,32 The serum levels of 
miR-206 are increased in mouse models of muscular dys-
trophy and amyotrophic lateral sclerosis.33 In a SMA mouse 
model, miR-206 levels in muscle was found to be activated 
and provided a survival mechanism to delay SMA neurode-
generation, although this was not sufficient to rescue the 
integrity of motor neurons.34
Here, we examined the abundance of three miRNAs, miR-
9, miR-206, and miR-132, in spinal cord, skeletal muscle, 
and serum samples from two SMA transgenic mouse models 
with severe and mild phenotypes,35 respectively, at different 
disease stages. These miRNAs were selected based on their 
potential involvement in motor neuron survival and differen-
tiation, skeletal muscle development and in the pathogenesis 
of SMA. miR-9 was selected as a representative neuron-
specific miRNA; miR-206 was selected as a representative 
muscle-specific miRNA; miR-132 was selected as a repre-
sentative miRNA which is expressed in both central nervous 
and peripheral tissues. In addition, we studied the response 
of these miRNAs to effective AON therapy. Finally, we mea-
sured the level of the same miRNAs in serum samples from 
patients affected by type II and type III SMA. Our study indi-
cates that miRNAs in serum have the potential to serve as 
informative biomarkers for SMA, to monitor disease progres-
sion and response to effective experimental therapy in future 
clinical studies.
Results
Alteration of miR-9, miR-206, and miR-132 in spinal cord 
and skeletal muscle tissues from SMA mice and their 
response to AON treatment
To measure the abundance of the three candidate miRNAs, 
reverse transcription-quantitative real-time polymerase chain 
reaction (PCR) analyses were performed on RNA prepared 
from spinal cord and tibialis anterior (TA) muscles harvested 
from 10-day-old SMA mice, including the severe type I SMA-
like mice (SMA-I), the mild type III SMA-like mice (SMA-III), 
and heterozygous littermate controls (control) which pre-
sented no phenotype. Spinal cords and muscles were also 
collected from 10 days old SMA-I mice that received a sin-
gle dose of 40 µg/g PMO25 via subcutaneous injection at 
postnatal day 0 (PND0), the AON strategy we have reported 
previously.6,36 The treated SMA-I mice showed dramatic 
improvement in their general condition: the average survival 
was increased from ~10 days to over 200 days; the body 
weight was increased to approximately 80% of the unaf-
fected littermate controls; and motor functions such as right-
ing reflex in young mice was completely corrected to normal 
level.6,36 The neuromuscular pathologies, including muscle 
fibre size and neuromuscular junction maturation, were both 
significantly improved although still slightly inferior to those in 
unaffected control mice.36
Small RNA TaqMan assays designed to detect only 
the mature miRNA species were used for all the miRNAs. 
 Significant differences among the groups of SMA-I, SMA-III 
and controls in all the three miRNAs, and in samples col-
lected from both spinal cords and TA muscles were detected 
(Figure 1).
There was significant downregulation of miR-9 in the spi-
nal cord of SMA-I mice compared with the controls (P < 
0.05, Figure 1a). In contrast, in skeletal muscle, miR-9 was 
increased over threefold in SMA-I mice compared with con-
trols (P < 0.05, Figure 1b). After systemic PMO25 treatment, 
miR-9 was reduced to near-normal level in skeletal muscle 
but not in spinal cord.
In both spinal cord and skeletal muscle, miR-206 was 
increased in SMA-I mice compared with controls (P < 0.05 
and P < 0.01, respectively). There was no significant change 
in miR-206 level in SMA-I mice in response to PMO25 treat-
ment, either in spinal cord or in skeletal muscle.
Reduction of miR-132 occurred in the spinal cord tissue of 
SMA-I mice (P < 0.05, Figure 1a), while the level in skeletal 
muscle was significantly increased (approximately 2.5-fold) 
compared to controls (P < 0.05, Figure 1b). After PMO25 
treatment, the altered miR-132 level in both spinal cord and 
skeletal muscle were completely reversed to normal levels (P 
< 0.01 and P < 0.05 compared to SMA-I mice; no significant 
difference to control mice).
In mild SMA-III mice, the level of the three miRNAs in spinal 
cord and skeletal muscle was altered at intermediate levels 
between what found in the severe SMA-I and the control mice 
(Figure 1). One-way analysis of variance showed that there 
was a significant difference in the level of the three miRNAs 
in skeletal muscle and spinal cord among groups of SMA-I, 
SMA-III and control mice (P< 0.05).
In addition, all three miRNAs showed a tissue-dependent 
abundance pattern. In keeping with its predominant central 
nervous system expression pattern, miR-9 was far more 
abundant in spinal cord than in skeletal muscle. Using real-
time PCR assay, in control mice we detected approximately 
500 times higher miR-9 levels in spinal cord (Ct value ~23) 
than in skeletal muscle (Ct value ~32). miR-206 had the high-
est level in skeletal muscle compared to the other two miR-
NAs. The level of miR-206 in skeletal muscle (Ct value ~20) 
was over 1,000 times higher than that in spinal cord (Ct value 
~30). In contrast to miR-9 and miR-206, miR-132 in skeletal 
muscle (Ct value ~27) and spinal cord (Ct value ~26) showed 
similar levels.
Serum miRNAs change dynamically with disease 
progression and following AON treatment
Serum miRNAs are promising biomarkers in Duchenne and 
Becker muscular dystrophy and in other types of muscular 
dystrophies and myopathies. They provide a noninvasive 
www.moleculartherapy.org/mtna
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measurement to monitor disease progression and response 
to therapy.14
To investigate how serum miRNAs change during disease 
progression and in response to AON treatment, SMA-I, SMA-
III, control, and SMA-I mice that had received PMO25 treat-
ment were sampled at different disease stages and serum 
miRNAs were quantified by real-time PCR.
As the lifespan of SMA-I mice is very limited with average 
survival of only 10 days, we measured serum miRNAs at 
presymptomatic PND2, mid-symptomatic PND7 and late-
symptomatic PND10 time points. The change in the serum 
level of the three miRNAs during disease progression was 
analyzed in SMA-I and control mice and was compared 
to the average level of each miRNA in the control group 
at PND2. We found a dynamic and fluctuating expression 
pattern of serum miRNAs in both SMA-I and control mice 
(Figure 2a).
In control mice, one-way analysis of variance showed sig-
nificant difference between the three time points in miR-9 
(P < 0.05), miR-206 (P < 0.05), and miR-132 (P = 0.05). 
Serum miRNAs levels fluctuated between PND2 and PND10. 
A steep decline of serum miR-206 (~14-fold reduction, P < 
0.05) occurred from PND2 to PND7. There was also signif-
icant decline in miR-132 (~6-fold reduction, P < 0.05) and 
miR-9 (~2.7-fold reduction, P < 0.05) from PND2 to PND7. 
The serum level of miRNAs was then increased from PND7 
to PND10, with 3.3-fold increase in miR-206 (P < 0.05), 3.1-
fold increase in miR-132 (P < 0.05) and miR-9 (P < 0.05) 
(Figure 2a). We also found that serum miR-9 abundance was 
generally lower than miR-206 and miR-132. For example, in 
control mice at PND10, the average Ct value was ~33 for 
miR-9, ~28 for miR-206 and miR-132.
In SMA-I mice, one-way analysis of variance showed no 
significant difference in serum miRNAs at the three time 
points measured in this study. Significant difference was 
only detected between PND2 and PND7 in all three miRNAs 
in serum, analyzed by t-test. There was 2.1-fold reduction 
in serum miR-9 (P < 0.05), 3.2-fold reduction in miR-206, 
and 2.7-fold reduction in miR-132 (P < 0.05). No significant 
difference was detected between PND7 and PND10 in all 
three miRNAs. miR-9 and miR-132 had a tendency towards 
increased levels at PND10 compared to PND7, but failed 
to reach statistical significance due to the high variation in 
the level of these miRNAs at the late symptomatic stage 
(Figure 2a).
At PND7, the mid-symptomatic stage in SMA-I, all three 
miRNAs were dramatically increased in SMA-I mice rela-
tive to controls, at approximately 4.4-fold in miR-9, 10-fold in 
miR-206, and 5-fold in miR-132 (Figure 2b). All three serum 
miRNAs responded remarkably well to systemic PMO25 treat-
ment and showed significant reduction to near-normal levels 
compared to the untreated SMA-I mice (P < 0.05, Figure 2b).
At PND10, the late-symptomatic stage in SMA-I, there were 
higher levels of all three miRNAs in SMA-I mice compared 
to controls (Figure 2), although only miR-132 reached sig-
nificance (P < 0.05, threefold change). The higher variation 
in serum miR-9 and miR-206 at the late stage of the disease 
could explain the lack of significant difference. Significant abun-
dance of all three miRNAs was observed in PMO25-treated 
SMA-I mice.
Figure 1 Relative quantification of miR-9, miR-206 and miR-132 in spinal cord and skeletal muscle samples in 10-day-old spinal 
muscular atrophy (SMA) transgenic mice. (a) Spinal cord samples were collected from severe type I (SMA-I, n = 6), mild type III (SMA-III, n 
= 6), severe type I that had received PMO25 treatment (SMA-I+PMO25, n = 6) and heterozygous unaffected littermate control mice (Het Ctrl, 
n = 6). There was significantly lower level of miR-9 and miR-132 and significantly higher level of miR-206 in severe type I SMA-like mice than 
in control. After PMO25 antisense oligonucleotide treatment, miR-132 was significantly increased to near-normal levels. (b) Tibialis anterior 
skeletal muscle samples were collected from each mouse group (n = 6 in each group). There was significantly higher level of all three miRNAs 
in skeletal muscle samples in the SMA-I mice than control. miR-9 and miR-132 significantly decreased to near-normal levels after PMO25 
antisense oligonucleotide treatment. Data are presented as mean ± standard error of the mean. *P < 0.05; **P < 0.01.
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The different levels of serum miR-9, miR-206, and miR-
132 on PND2, PND7, and PND10 suggests that the abun-
dance of miRNAs changes with disease progression and 
that the alteration of miRNAs in serum is more significant at 
mid-symptomatic than at the late-symptomatic stage. While 
serum miRNAs responded well at PND7 to PMO25 treat-
ment, all three miRNAs increased dramatically at PND10 
in PMO25 treated SMA-I mice compared to controls (P < 
0.01 and P < 0.001, Figure 2c). This result suggests that 
after a single-dose PMO25 treatment at PND0, the altered 
level of serum miRNAs can be corrected but only for a lim-
ited period, between 7–10 days in severe SMA mice, before 
they rebound to the active disease state levels. This is con-
sistent with the clinical phenotype of the PMO25 single-
dose treated mice that had partially rescued body weight, 
but that developed ear and tail necrosis, indicating active 
disease, at a later stage.6
Altered level of miRNAs in serum occurs prior to their 
change in spinal cord and skeletal muscle
Our study showed that alteration in serum miRNAs occurred 
much earlier than spinal cord and skeletal muscle miR-
NAs. At PND2, the presymptomatic stage in severe SMA-I 
mice, there was no significant difference in the abundance 
of all three miRNAs in either spinal cord or skeletal muscle 
between the SMA-I mice and controls. However, there was 
significant higher level of miR-9 and miR-132 in serum sam-
ples from SMA-I (3.5- and 2.5-fold, respectively) than that of 
control mice (Figure 3a).
The mild SMA-III mice show no loss of motor neurons in 
the anterior horn in comparison with normal littermates. The 
SMN protein expression in spinal cord from SMA-III mice is 
lower than that in control mice.35 We have previously shown 
that the SMA-III mice have the same body weight and right-
ing reflex motor function as the controls on PND10, albeit 
Figure 2 The level of miR-9, miR-206 and miR-132 in serum samples from spinal muscular atrophy (SMA) transgenic mice. (a) The 
level of the three miRNAs in serum samples collected from SMA-I mice and heterozygous controls at PND2 (n = 5 in each group), PND7 (n 
= 4 in each group), and PND10 (n = 6 in each group). Abundance data is relative to the miRNA level in heterozygous controls on PND2. (b) 
Significantly higher level of all three miRNAs in SMA-I mice (n = 4) compared to heterozygous controls (n = 4) at PND7. miR-9, miR-206, and 
miR-132 responded dramatically to PMO25 treatment (n = 4), and were significantly reduced relative to untreated SMA-I mice. No significance 
in the difference between PMO25-treated SMA-I and the control group. The level is relative to the average miRNA level in heterozygous 
controls. (c) Abundance of the three miRNAs in serum samples from untreated SMA-I (n = 6), SMA-I received PMO25 treatment (n = 6) and 
unaffected heterozygous control mice (n = 6) at PND10. The level is relative to the average miRNA level in heterozygous controls. Data are 
presented as mean ± standard error of the mean. *P < 0.05; **P < 0.01; ***P < 0.001.
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with slightly decreased size of skeletal muscle fibers and 
neuromuscular junction end plates.36 Ear and tail necrosis 
commence in these mice from 2–3 weeks old. In this study, 
SMA-III mice showed no significant alteration of miRNAs in 
spinal cord and skeletal muscle samples at PND10, com-
pared to control mice. However, the miRNAs in serum of 
SMA-III were all significantly increased at PND10 (miR-9 to 
threefold, miR-206 to eightfold, and miR-132 to sixfold control 
levels) (Figure 3b). These results suggest that the change 
of miRNA level in serum occurs before the change in spinal 
cord and muscle, in both SMA-I and SMA-III mice.
To detect the window in which the serum miRNA starts to 
change in SMA-III mice, we measured the level of serum miR-
NAs in SMA-III mice at PND7 and no change was detected 
(data not shown). This suggests the alteration of miRNA 
abundance in serum may commence between PND7-10 in 
SMA-III mice.
Altered levels of miRNAs in serum samples from SMA 
patients
To further evaluate the potential of miR-9, miR-206, and miR-
132 as noninvasive biomarkers, we examined the expression 
of these miRNAs in serum samples from SMA patients with 
type II (n = 6) and type III SMA (n = 4), aged between 4–14 
years old (Figure 4). Serum miRNAs were measured by real-
time quantitative PCR, relative to age-matched healthy con-
trols (n = 7). We found upregulation of miR-9 (2.36-fold) and 
miR-132 (1.54-fold) expression in type II SMA serum relative 
to healthy controls (P < 0.05, Figure 4a). In serum from type 
III SMA patients, these two miRNAs were at intermediate lev-
els between type II SMA and controls without significance 
in difference. There was no significant difference in the level 
of serum miR-206 from SMA patients compared to healthy 
controls (Figure 4a). There was no significant correlation 
between the level of the three miRNAs in serum and the 
motor functional ability of the patients, measured using the 
Hammersmith Functional Motor Scale (Figure 4b).
To determine if there is an association between the expres-
sion level of miRNAs in serum and the age of SMA patients, 
linear regression and correlation analyses were performed 
in serum samples from SMA patients and healthy controls 
(Figure 4c). Although there was a decrease in serum miR-9 
expression in SMA patients with increasing age, in contrast 
to the stable expression in healthy controls, there was no 
significant correlation between the expression of miR-9 and 
the age of SMA patients. Similarly, there was no correlation 
between the expression level of miR-206 and miR-132 with 
age in SMA patients and healthy controls. Our data therefore 
suggest that there is no significant correlation between the 
expression levels of the three miRNAs in serum samples with 
age in SMA patients.
Discussion
We have characterized the differential expression of miR-9, 
miR-206, and miR-132 in spinal cord, skeletal muscle and 
serum from SMA and control mice, and in serum samples 
from SMA and control patients. A systematic analysis of 
miRNA expression was conducted in SMA mice with differ-
ent severities (severe SMA-I and mild SMA-III) at different 
disease stages (presymptomatic, mid-symptomatic and late 
stage) and their responses to therapeutic AON treatment. 
This is the first study to assess the potential of selected miR-
NAs as biomarkers in SMA.
As a highly conserved neuronal-specific miRNA, miR-9 is 
involved in the neuronal development, including the regula-
tion of neuronal progenitor proliferation and the maturation 
Figure 3 The level of miR-9, miR-206 and miR-132 in SMA-I mice at PND2 and in SMA-III mice at PND10. (a) Abundance of the three 
miRNAs in spinal cord, skeletal muscle, and serum collected from SMA-I mice and controls at PND2 (n = 5 in each group). (b) Level of 
miRNAs in spinal cord, skeletal muscle, and serum from SMA-III and control mice at PND10 (n = 4–6 in each group). The miRNA level in 
spinal muscular atrophy (SMA) mice was normalized to the level in controls. Data are presented as mean ± standard error of the mean. *P < 
0.05; **P < 0.01.
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and differentiation of postmitotic neurons.37 miR-9 has also 
been found to be altered in other neurodegenerative dis-
orders. It is decreased in the brain of Alzheimer’s disease 
patients38 and increased in the cortex of Parkinson’s disease 
patients.39
The reduction of miR-9 level in spinal cord tissue in severe 
SMA mice in our study is consistent with the phenotype of 
motor neuron degeneration which characterizes the late stage 
of the disease in the mice, and also in line with the finding in 
SMN1 mutated motor neurons, where miR-9 is decreased 
in cultured motor neurons harboring SMN1  mutation.19 The 
conversely increased level of miR-9 in TA muscles is con-
sistent with a report that miR-9 is upregulated in fibroblasts 
with SMN protein deficiency.40 miR-132 also has contrary 
abundance in spinal cord and skeletal muscle. miR-132 plays 
an important role in neurite outgrowth.22 The reason for the 
contrary tendency of miR-9 and miR-132 level in spinal cord 
and skeletal muscle in SMA mice is not known.
miR-206 is increased in skeletal muscle in SMNΔ7 mice, at 
the advanced stage of the pathology (PND10/12), but not in 
the early phase (PND5).34 Similarly, we found that miR-206 
was significantly increased in both spinal cord and TA muscle 
in the severe SMA mice at the late stage of the disease. It 
has been speculated that miR-206 upregulation is a protec-
tive response to the severe defect in neuromuscular junction 
maturation in SMA mice.34
In SMA-I mice, there were clearly detectable altered levels 
of miR-9 and miR-132 in serum as early as at PND2, but 
there was no change of these two miRNAs in either spinal 
cord or skeletal muscle at this presymptomatic time point 
(Figure 3a). Similarly, at PND10, the alterations of miRNAs 
in serum of SMA-III mice were more dramatic than in spinal 
cord and skeletal muscle (Figure 3b). These results indi-
cate that the change in abundance of miR-9 and miR-132 in 
serum are more prominent than that in spinal cord or muscle, 
and show the potential of these two miRNAs as noninvasive 
candidate biomarkers for this disease.
miRNAs that are highly enriched in serum than in skele-
tal muscle have also been reported in mdx mice and DMD 
patients relative to controls.16,41,42 It has been proposed that, 
Figure 4 The level of miR-9, miR-206, and miR-132 in serum from type II and type III spinal muscular atrophy (SMA) patients and 
healthy controls. (a) Relative quantification of miRNAs in serum samples from type II (n = 6) and type III (n = 4) SMA patients and age-
matched healthy controls (n = 7). The abundance of miRNAs was normalized to the spiked-in C. elegans miRNA (cel-miR-39). Data are 
presented as mean ± standard error of the mean. (b) The correlation between the level of the miRNAs and the Hammersmith Functional Motor 
Scale was studied by linear regression analyses. (c) The level of three miRNAs in serum samples from SMA patients (n = 10) and healthy 
controls (n = 7) at different ages. The regression line is presented.
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in DMD, the serum dystromiRs are released by regenerating 
and/or degenerating mature fibres and the miRNAs in cir-
culation are protected from RNase-mediated degradation by 
either associated with Argonaute-2 protein or complexing with 
lipoproteins.16,43 This is possible for miR-206, as it is enriched 
in skeletal muscle. miR-9 and miR-132 are not muscle-spe-
cific. The more dramatic change of miR-9 and miR-132 in 
serum than in skeletal muscle and spinal cord may suggest 
that there might be organs other than, or in addition to, spinal 
cord and skeletal muscle, from which these serum miRNAs 
originate. This may imply that additional organs, beyond spi-
nal cord and skeletal muscle, could contribute to the SMA 
disease pathogenesis. Indeed, increasing numbers of clinical 
and experimental studies indicate the involvement of addi-
tional peripheral organs in the pathogenesis of the disease in 
severe cases.1,44 We have previously shown that regular sys-
temic administration of morpholino AON in an intermediate 
SMA mouse model from birth until adulthood provided thera-
peutic benefit and rescued the SMA phenotypes, presumably 
via peripheral SMN restoration.36 Possible candidates for the 
peripheral involvement include perisynaptic Schwann cells at 
neuromuscular junctions45 and dorsal root ganglia,46 as they 
are likely to benefit more from the peripheral rather than the 
exclusive CNS delivery of morpholino AON. Further investi-
gation of miR-9 and miR-132 in the peripheral neuronal sys-
tem will help to understand the molecular mechanism of their 
involvement in SMA.
Vascular defects have been reported in some severe 
cases of SMA infants and mouse models. These include digi-
tal necrosis and distal vascular thrombosis in severe SMA 
infants,47,48 decreased vascular density in skeletal muscle,26 
spinal cord27 and intestine49 in SMA mice, and defective 
microvascular development in skeletal muscle in severe SMA 
patients.27 miRNAs play a crucial role in the biogenesis and 
function of endothelial cells50 and are implicated as dynamic 
regulators of cardiac and vascular signalling and pathophysi-
ology51 and diabetic vasculopathy.52 miR-132 is involved in 
the proliferation of endothelial cells and has been implicated 
in neovascularisation.25 Further studies on miR-132 in vas-
cular function in SMA are required to understand its involve-
ment in the pathogenesis of SMA vasculopathy.
We have previously reported the successful rescue of 
severe SMA mice by PMO25 treatment when delivered in 
newborn litters.6 While all parameters measured were dra-
matically improved, some features, for example, the body 
weight, skeletal muscle fibre size, and neuromuscular junc-
tion maturation, were still not completely rescued when com-
pared to the unaffected controls. The single-dose treated 
mice also displayed ear and tail necrosis at a later stage6,36 
It is therefore not surprising to see more elevated miRNAs 
levels at PND10 in the treated SMA mice than in unaffected 
controls (Figure 2c). However, the early significant response 
of serum miR-206 and miR-132 to PMO25 treatment at 
PND7 (Figure 2b) indicates the potential of miRNAs as bio-
marker of response to therapeutic intervention, although the 
response is transient and time limited. This result may also 
suggest a requirement for repeated AON treatment in SMA 
in order to maintain the therapeutic effect. Indeed, the clini-
cal benefit of repeated administrations of AON has already 
been confirmed in a preclinical study36 and such regime is 
now being applied in clinical trial (www.clinicaltrials.org, ID: 
NCT02386553).
In SMA patients, there was significantly higher level of 
miR-9 and miR-132 in serum compared to healthy controls, 
and SMA-II patients had higher level of miRNAs than SMA-III 
patients (Figure 4). However, the lack of correlation between 
the level of serum miRNAs and Hammersmith Functional 
Motor Scale indicates the possibility that high interpatient 
variability may limit the use of these miRNAs as biomarkers 
for SMA, especially given the modest fold changes observed. 
In addition, the fact that the serum miR-206 level change is 
significant in SMA mice but not in SMA patients suggests the 
differential abundance of some miRNAs between patients 
and mouse models. While this study examined only three 
miRNAs selected based on literature reports, it provides use-
ful information for future more in-depth studies on developing 
miRNAs as biomarkers in SMA. In the future, deep microRNA 
profiling in SMA patients, using the advanced next genera-
tion sequencing technology, may provide more potential bio-
marker candidates.
In summary, we have shown that miR-9, miR-206, and 
miR-132 are differentially expressed in spinal cord, skeletal 
muscle, and serum in SMA mouse models. Serum miRNAs 
in SMA may be altered prior to the change in spinal cord and 
skeletal muscle tissues and before the appearance of any 
clinical phenotypes. miR-132 in spinal cord, skeletal muscle, 
and serum responds dramatically, although transiently, to 
systemic AON treatment in the severe mouse model. Serum 
miR-132 shows the greatest potential, among the three miR-
NAs tested in this study, as a candidate biomarker of disease 
progression and therapeutic response in SMA. Given that 
encouraging clinical trials are currently undertaking in SMA 
patients, our findings indicate the potential clinical application 
of miRNA as promising noninvasive biomarker candidate for 
this disease.
Materials and methods
Oligonucleotides. The 25-mer therapeutic antisense Phos-
phorodiamidate Morpholino Oligomer PMO25, to augment 
exon 7 inclusion in SMN2, was synthesized by Gene Tools 
LLC with agreement for research usage only. The sequence 
of PMO25 has been previously described.6 Products were 
dissolved to standard concentrations and stored according to 
the manufacturer’s instructions.
Animals. All mouse experiments were performed accord-
ing to protocols approved by University College London 
Biological Services and UK Home Office under the Ani-
mals (Scientific Procedures) Act 1986. The initial breeding 
pairs of SMA transgenic mice FVB.Cg-Tg(SMN2)2Hung 
Smn1tm1Hung/J, originally created by Hsieh-Li et al.,35 were 
purchased from the Jackson Laboratory (TJL005058). The 
severe type I SMA-like mice, referred as “SMA-I”, carry two 
copies of human SMN2 transgene with genotype (SMN2)2+ /–; 
Smn–/–; the mild type III SMA-like mice, referred as “SMA-III”, 
carry four copies of human SMN2 transgene with genotype 
(SMN2)2+ /+; Smn–/–; and the heterozygous progeny with geno-
type (SMN2)2+ /–; Smn+/– is phenotypically unaffected and was 
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used as unaffected littermate control, referred as “control”. 
Subcutaneous injections in severe type I SMA-like mice were 
performed as described previously.6 40 µg/g PMO25 was 
injected subcutaneously in SMA-I mice at PND0. The treated 
mice were referred as “SMA-I + PMO25”.
SMA patients and healthy controls serum cohort. The study 
was approved by the Berkshire Research Ethics Committee 
(REC reference 05/MRE12/32). Serum samples were sup-
plied by the MRC Center for Neuromuscular Diseases Bio-
bank London (REC reference number 06/Q0406/33, http://
www.cnmd.ac.uk) and were collected from individuals under 
written informed consent of parents or legal guardians. The 
Declaration of Helsinki protocols were followed. Serum sam-
ples were collected from six SMA type II patients and four 
SMA type III patients (age range between 4 to 14 years) from 
the SMA clinic at Great Ormond Street Hospital, London. 
All patients have confirmed genetic diagnosis of SMA with 
homozygous genomic deletion in SMN1 gene and two or 
three copies of SMN2 gene.
RNA preparation in spinal cord and skeletal muscle samples 
from SMA mice.  Spinal cord and TA skeletal muscle samples 
were collected from 2 day old (n = 5 for SMA-I, n = 5 for 
control), 7 day old (n = 4 for SMA-I, n = 4 for SMA-III, n = 
4 for SMA-I+PMO25, n = 5 for control), and 10 day old (n = 
6 in each group of mice). Samples were immediately snap 
frozen in liquid nitrogen after dissection and stored at −80 °C 
for RNA processing. Mouse tissues were homogenized using 
Precellys Homogenizer (Bertin Technologies) in lysis buffer. 
Total RNA was extracted using miRNeasy kit (QIAGEN) fol-
lowing the manufacturer’s protocol for tissue samples.
RNA extraction in serum samples collected from SMA mice 
and patients. In mice, blood samples were collected from 
the right atrium immediately after the mice were culled. In 
patients, serum samples were prepared from 1.5 to 4 ml of 
blood taken in BD vacutainer tubes. The blood sample was 
allowed to clot at room temperature for 30 minutes, followed 
by centrifugation at 2,850 g for 10 minutes. Serum superna-
tant was carefully collected and stored at −80 °C until use.
Total RNA was extracted from serum samples using miR-
Neasy Serum/Plasma kit (QIAGEN) following the manufac-
turer’s protocol for liquid samples. For data normalization, we 
used an artificial Caenorhabditis elegans cel-miR-39 added 
at 25 fmol in a 5 µl volume as previously described.14,53
Reverse transcription and qRT-PCR analysis. Quanti-
tative RT-PCR was performed using hsa-miR-9 (Cat. 
4427975_002231), hsa-miR-206-3p (Cat. 4427975_000510), 
hsa-miR-132-3p (Cat. 4427975_000457), cel-miR-39 (Cat. 
4427975_000200) and U6 snRNA (Cat. 4427975_001973) 
TaqMan small RNA Assay (Life Technology) following 
the manufacturer’s protocol and the methods previously 
described.14 Briefly, a fixed volume of 5 µl of total RNA (10 ng) 
of a given sample was reverse transcribed using TaqMan 
MicroRNA Reverse Transcription kit. The PCR amplification 
of a volume of 1.33 µl cDNA was carried out using TaqMan 
Universal PCR master mix and miRNA-specific stem-loop 
primers (Life Technology). The relative expression of miRs 
was analyzed by ΔΔCt method. U6 snRNA was used as 
endogenous control for data normalization in spinal cord and 
muscle tissues, and the artificial spiked in cel-miR-39 was 
used as endogenous control in serum samples.
Statistical analysis. One-way analysis of variance and post 
t-test were used to determine statistical significance when 
comparing three and four groups of mice. Student t-test was 
used for statistical analysis of two groups of data. Data are 
presented as mean ± standard error of the mean. GraphPad 
Prism 5.0 software (GraphPad Software) was used for statis-
tical analysis and graph design.
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